Santhera Pharmaceuticals (SPHDF) Stock Price, News & Analysis

Company Overview

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative therapies for rare neuromuscular and pulmonary diseases. Headquartered in Pratteln, Switzerland, the company concentrates on addressing high unmet medical needs in conditions such as Duchenne muscular dystrophy (DMD), limb‐girdle muscular dystrophies and other mitochondrial or neuromuscular disorders. Santhera’s corporate strategy emphasizes both in‐house development and strategic partnerships to advance its drug candidates through clinical trials and bring approved therapies to market.

The company’s flagship marketed product is Raxone (idebenone), a synthetic analogue of coenzyme Q10 that received marketing authorization in Europe for the treatment of visual impairment in patients with Leber’s hereditary optic neuropathy (LHON). In addition to Raxone’s role in LHON, Santhera has expanded the use of idebenone under the brand name Puldysa in certain European countries for the maintenance of respiratory function in patients with DMD. Santhera’s pipeline includes vamorolone, a novel corticosteroid analogue being developed in collaboration with ReveraGen BioPharma for boys with DMD, as well as earlier‐stage programs targeting rare mitochondrial and muscle disorders.

Santhera serves patients and healthcare providers across Europe and North America through a network of subsidiaries and distribution partners. The company was founded in the mid‐1990s and maintains research and commercial operations in key markets, including Germany, Italy and the United States. Santhera continues to leverage its expertise in rare disease drug development, regulatory strategy and patient advocacy to expand its portfolio and reach, aiming to deliver new treatment options for underserved patient populations.

Key Stats

• Today's Range: $23.25 to $23.25
• 50-Day Range: $23.25 to $23.25
• 52-Week Range: $12.28 to $23.25
• Volume: N/A
• Average Volume: 1,521 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 7/22/2026
• Next Earnings (Estimated): 9/21/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SPHDF
• CIK: N/A
• Web: www.santhera.com
• Phone: (161) 906-8950
• Fax: N/A
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A